No Data
RemeGen Co. Ltd. Class H (9995) Was Downgraded to a Hold Rating at J.P. Morgan
RemeGen Narrows Loss by 3% in 2024
Hong Kong stock movement | REMEGEN (09995) rises over 12% with last year's revenue increasing by 58.92%. Sales of core products continue to grow significantly.
REMEGEN (09995) rose over 12%, as of the time of writing, it is up 12.13%, priced at 24.95 HKD, with a trading volume of 0.157 billion HKD.
REMEGEN's 2024 Earnings Reports: Commercialization accelerates, losses narrow, and high investment in research and development continues to pressure cash flow.
① In 2024, REMEGEN achieved revenue of 1.415 billion yuan, a year-on-year increase of 58.5%; the annual net loss attributable to the parent company was 1.468 billion yuan, a reduction in loss of 2.84% compared to the previous year; ② Long-term high research and development has placed significant cash flow pressure on REMEGEN.
Rongchang Biotech: Summary of Rongchang Biotech\'s 2024 Annual Report
Rongchang Biotech: Rongchang Biotech 2024 Annual Report
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 29% But Its Business Is Yet to Catch Up
